The U.S. Small Business Administration has been facilitating more loans than ever before. Image via Getty Images

The U.S. Small Business Administration’s Houston district saw a nearly 25 percent increase this year in the dollar amount of the most popular type of SBA loan compared with the pre-pandemic year of 2019.

A new report from the SBA shows small businesses in the 32-county district received $1.3 billion in 7(a) loans in fiscal 2021 compared with almost $1.05 billion in pre-pandemic 2019. Borrowers in the SBA-backed 7(a) program can obtain loans of up to $2 million. The length of each loan is 25 years for real estate deals and seven years for working capital.

“The SBA continues to make headway in helping small businesses access much-needed capital, but much more work remains to be done,” Patrick Kelley, associate administrator for the SBA’s Office of Capital Access, says in a news release.

In terms of the number of 7(a) loans extended in the Houston district, the top lenders for fiscal 2021 were:

  • Wallis-based Wallis Bank
  • San Francisco-based Wells Fargo
  • Columbus, Ohio-based United Midwest Savings Bank
  • Birmingham, Alabama-based BBVA USA (now part of Pittsburgh-based PNC Bank)
  • Wilmington, North Carolina-based Live Oak Bank, the country’s most active 7(a) lender.

The top 7(a) lenders by total dollar amount of loans were:

  • Wallis Bank
  • Live Oak Bank
  • Humble-based Plains State Bank
  • San Antonio-based Frost Bank
  • Kingswood-based The Mint National Bank

The SBA’s Houston district is home to more than 600,000 small businesses in a 32-county region that includes the nine counties in the Houston metro area: Austin, Brazoria, Chambers, Fort Bend, Galveston, Harris, Liberty, Montgomery, and Waller.

Nationwide, the SBA backed $36.5 billion in 7(a) loans in fiscal 2021. Nearly $11 billion went to minority-owned businesses, $5 billion to woman-owned businesses, and $1.2 billion to veteran-owned businesses.

SBA lending could experience an uptick in fiscal 2021 due to inflation. An October 2021 survey conducted for the U.S. Chamber of Commerce and MetLife found 45 percent of small businesses had taken out loans to cope with rising inflation; among retailers, that figure was 58 percent. In the survey, 74 percent of small business owners expressed concern about inflation.

“Small business owners’ optimism is plowing through economic uncertainty, but they now face new obstacles with rising inflation, labor shortages, and supply chain challenges,” Tom Sullivan, vice president for small business policy at the U.S. Chamber of Commerce, says in a news release.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”